An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model

@article{Ubah2019AnAV,
  title={An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model},
  author={Obinna C. Ubah and J. Steven and A. Porter and C. Barelle},
  journal={Frontiers in Immunology},
  year={2019},
  volume={10}
}
  • Obinna C. Ubah, J. Steven, +1 author C. Barelle
  • Published 2019
  • Medicine
  • Frontiers in Immunology
  • Tumor necrosis factor-alpha (TNF-α), an established pro-inflammatory cytokine plays a central role in the induction and progression of several chronic inflammatory and autoimmune diseases. Targeting TNF-α as a treatment modality has shown tremendous success, however there are several limitations associated with the current anti-TNF-α biologic drugs including: immunogenicity, life-threatening infections, resistance to treatment, complexity of manufacture and cost of treatment. Here, we report… CONTINUE READING
    4 Citations

    References

    SHOWING 1-10 OF 96 REFERENCES
    A New Venue of TNF Targeting
    • 32
    • PDF
    Anti-TNF therapy: past, present and future.
    • 230
    • PDF
    Anti-TNF-α antibody allows healing of joint damage in polyarthritic transgenic mice
    • 97